Use, Safety, and Efficacy of Single-Patient Use of the US Food and Drug Administration Expanded Access Program

Ähnliche Einträge

• Availability of Investigational Medicines Through the US Food and Drug Administration’s Expanded Access and Compassionate Use Programs
  von: Puthumana, Jeremy, et al.
  Veröffentlicht: (2018)
• The Impact of the US Food and Drug Administration Chlorofluorocarbon Ban on Out-of-pocket Costs and Use of Albuterol Inhalers Among Individuals With Asthma
  von: Jena, Anupam B., et al.
  Veröffentlicht: (2015)
• Radium‐223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program
  von: Sartor, Oliver, et al.
  Veröffentlicht: (2017)
• Right now, in the right way: U. S. Food and Drug Administration’s expanded access program and patient rights
  von: Holbein, M. E. Blair, et al.
  Veröffentlicht: (2018)
• Impact of the US Food and Drug Administration registration of antiretroviral drugs on global access to HIV treatment
  von: Chahal, Harinder Singh, et al.
  Veröffentlicht: (2018)